Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743

Carmen Belli

Carmen Belli, MD, PhD, Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Steven G. Gray, PhD, Thoracic Oncology Research Group, Trinity St James's Cancer Institute, St James's Hospital, Dublin, Ireland; Francesco Masedu, PhD, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; and Luciano Mutti, MD, PhD, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy, Italian Group for Mesothelioma and Environmental Oncology (G.I.Me.), Voghera (PV), Italy

Steven G. Gray

Carmen Belli, MD, PhD, Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Steven G. Gray, PhD, Thoracic Oncology Research Group, Trinity St James's Cancer Institute, St James's Hospital, Dublin, Ireland; Francesco Masedu, PhD, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; and Luciano Mutti, MD, PhD, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy, Italian Group for Mesothelioma and Environmental Oncology (G.I.Me.), Voghera (PV), Italy

Francesco Masedu

Luciano Mutti

Carmen Belli, MD, PhD, Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Steven G. Gray, PhD, Thoracic Oncology Research Group, Trinity St James's Cancer Institute, St James's Hospital, Dublin, Ireland; Francesco Masedu, PhD, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; and Luciano Mutti, MD, PhD, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy, Italian Group for Mesothelioma and Environmental Oncology (G.I.Me.), Voghera (PV), Italy